In last trading session, Fortress Biotech Inc (NASDAQ:FBIO) saw 0.41 million shares changing hands with its beta currently measuring 1.66. Company’s recent per share price level of $2.03 trading at -$0.05 or -2.40% at ring of the bell on the day assigns it a market valuation of $56.04M. That closing price of FBIO’s stock is at a discount of -42.36% from its 52-week high price of $2.89 and is indicating a premium of 33.0% from its 52-week low price of $1.36. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.89 million shares which gives us an average trading volume of 656.10K if we extend that period to 3-months.
For Fortress Biotech Inc (FBIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 1 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.75 in the current quarter.
Fortress Biotech Inc (NASDAQ:FBIO) trade information
Upright in the red during last session for losing -2.40%, in the last five days FBIO remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $2.03 price level, adding 13.98% to its value on the day. Fortress Biotech Inc’s shares saw a change of 0.25% in year-to-date performance and have moved -4.25% in past 5-day. Fortress Biotech Inc (NASDAQ:FBIO) showed a performance of -9.78% in past 30-days. Number of shares sold short was 2.62 million shares which calculate 4.57 days to cover the short interests.
Fortress Biotech Inc (FBIO) estimates and forecasts
Statistics highlight that Fortress Biotech Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 3.05% of value to its shares in past 6 months, showing an annual growth rate of 61.28% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -31.22% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.58M for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 22.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 58.60% while estimates for its earnings growth in next 5 years are of 25.50%.
Fortress Biotech Inc (NASDAQ:FBIO)’s Major holders
Insiders are in possession of 21.21% of company’s total shares while institution are holding 15.78 percent of that, with stock having share float percentage of 20.03%. Investors also watch the number of corporate investors in a company very closely, which is 15.78% institutions for Fortress Biotech Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 470.54 shares of worth $0.96 million or 1.70% of the total outstanding shares. The later fund manager was in possession of 152.47 shares on Sep 30, 2024 , making its stake of worth around $0.31 million in the company or a holder of 0.55% of company’s stock.
